NCT04263090 2024-05-09
Rigosertib Plus Nivolumab for KRAS+ NSCLC Patients Who Progressed on First-Line Treatment
Icahn School of Medicine at Mount Sinai
Phase 1/2 Completed
Icahn School of Medicine at Mount Sinai
University of Kansas Medical Center
H. Lee Moffitt Cancer Center and Research Institute